BSFA vs. VAL, ROQ, IXI, EVG, APTA, FAB, GENF, OCTP, PYC, and NFX
Should you be buying BSF Enterprise stock or one of its competitors? The main competitors of BSF Enterprise include ValiRx (VAL), Roquefort Therapeutics (ROQ), IXICO (IXI), Evgen Pharma (EVG), Aptamer Group (APTA), Fusion Antibodies (FAB), Genflow Biosciences (GENF), Oxford Cannabinoid Technologies (OCTP), Physiomics (PYC), and Nuformix (NFX). These companies are all part of the "biotechnology" industry.
ValiRx (LON:VAL) and BSF Enterprise (LON:BSFA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking.
0.1% of ValiRx shares are held by institutional investors. 16.7% of ValiRx shares are held by insiders. Comparatively, 54.6% of BSF Enterprise shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
BSF Enterprise is trading at a lower price-to-earnings ratio than ValiRx, indicating that it is currently the more affordable of the two stocks.
ValiRx has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, BSF Enterprise has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.
ValiRx received 147 more outperform votes than BSF Enterprise when rated by MarketBeat users. However, 75.00% of users gave BSF Enterprise an outperform vote while only 51.55% of users gave ValiRx an outperform vote.
ValiRx's return on equity of -35.56% beat BSF Enterprise's return on equity.
In the previous week, ValiRx had 4 more articles in the media than BSF Enterprise. MarketBeat recorded 4 mentions for ValiRx and 0 mentions for BSF Enterprise. BSF Enterprise's average media sentiment score of 0.56 beat ValiRx's score of 0.00 indicating that ValiRx is being referred to more favorably in the media.
Summary
BSF Enterprise beats ValiRx on 7 of the 12 factors compared between the two stocks.
Get BSF Enterprise News Delivered to You Automatically
Sign up to receive the latest news and ratings for BSFA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BSFA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BSF Enterprise Competitors List
Related Companies and Tools
